University of Pennsylvania drives new discoveries in cancer immunotherapy research on an international scale, and pioneered the first FDA-approved CAR-T cell therapy. Penn’s award-winning doctors and scientists focus on training immune cells to recognize and hunt cancer cells. PICI at Penn extends this work and supports laboratory studies and clinical trials, recruitment of talented new faculty and opportunities for early-career investigators who will train at Penn. Carl June, MD | Director E. John Wherry, PhD | Co-Director All Investigators Related Our Impact, Press Release, Research Update For Advanced Pancreatic Cancer, Combining Immunotherapies with Chemotherapy Shows Early Promise in Reducing Tumor Size Clinical Trial The PRINCE Trial Research Update A Bubble of Hope for Cancer: the Exosome in Immunotherapy Press Release Parker Institute researchers publish first major scientific paper in Nature Announcement PICI Hosts 2024 Spring Scientific Retreat Press Release BostonGene and the Parker Institute for Cancer Immunotherapy Collaborate to Generate Comprehensive Longitudinal Multi-Omic Data for Predicting Immunotherapy Outcomes Announcement, From Bench to Fireside Episode Nine: Katie Campbell, PhD Announcement PICI Network Investigators to Unveil Cancer Research Breakthroughs at AACR 2024 Announcement, From Bench to Fireside Episode Eight: Robbie Majzner, MD
Our Impact, Press Release, Research Update For Advanced Pancreatic Cancer, Combining Immunotherapies with Chemotherapy Shows Early Promise in Reducing Tumor Size
Press Release BostonGene and the Parker Institute for Cancer Immunotherapy Collaborate to Generate Comprehensive Longitudinal Multi-Omic Data for Predicting Immunotherapy Outcomes